about
Natural Products: Insights into Leishmaniasis Inflammatory ResponseRegulation of immunity during visceral Leishmania infectionDeficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovaniSuccessful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 ProductionLeishmania infantum-chagasi activates SHP-1 and reduces NFAT5/TonEBP activity in the mouse kidney inner medulla.Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.Dependency of B-1 Cells in the Maintenance of Splenic Interleukin-10 Producing Cells and Impairment of Macrophage Resistance in Visceral LeishmaniasisAnti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance.Animal models for the study of leishmaniasis immunology.Immune regulation during chronic visceral leishmaniasis.Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.Expression of leukosialin (CD43) defines a major intrahepatic T cell subset associated with protective responses in visceral leishmaniasisTherapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasisToll-Like Receptor 2 Targeted Rectification of Impaired CD8⁺ T Cell Functions in Experimental Leishmania donovani Infection Reinstates Host ProtectionInduction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovaniLive Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.Glycyrrhizic acid-mediated subdual of myeloid-derived suppressor cells induces antileishmanial immune responses in a susceptible host.Visceral leishmaniasis during pregnancy: A rare case report from Greece.Discovery of 3,3'-diindolylmethanes as potent antileishmanial agents.Leishmania infantum-specific production of IFN-γ and IL-10 in stimulated blood from dogs with clinical leishmaniosis.Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood.Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.Exploring the role of medicinal plant-based immunomodulators for effective therapy of leishmaniasis.The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis.Leishmania vaccine development: exploiting the host-vector-parasite interface.In vivo characterization of two additional Leishmania donovani strains using the murine and hamster model.Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis.Comprehensive candidate gene analysis for symptomatic or asymptomatic outcomes of Leishmania infantum infection in Brazil.Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.Hepatic stellate cells regulate liver immunity to visceral leishmaniasis through P110δ-dependent induction and expansion of regulatory T cells in mice.Targeted Immunology for Prevention and Cure of VL.Galectin-1 Impairs the Generation of Anti-Parasitic Th1 Cell Responses in the Liver during Experimental Visceral Leishmaniasis.The Equivocal Role of Th17 Cells and Neutrophils on Immunopathogenesis of Leishmaniasis.Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice.Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis.T cell suppression in the bone marrow of visceral leishmaniasis patients: impact of parasite load.Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection.Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
P2860
Q26779924-84B7AC17-0C4D-427F-8233-39D432BE94A2Q28066034-AD3F4D5A-825B-4EA4-BFB0-84E02A64A162Q28539842-53B0565A-E723-4F75-BF27-59D3A4DD7030Q28550696-2214383A-273A-430D-B103-A1DF9A977E5DQ31171204-817F1F84-F5C8-4724-BC14-1CC0539BE965Q33659753-DD966B0F-CCB3-4C78-ADD0-B2B428A28AADQ33753224-2700DF48-062C-459C-93CB-4F764A1CECC5Q33849243-7EF83B04-036A-4728-8290-503057B5C079Q33859617-46F0A59D-5441-4D09-BD68-55D9FDDFA2D5Q33881718-D1D3AAA3-B13D-4543-9964-2ADD2275ED71Q34955529-404A1C36-43BA-422D-96BF-BBFA44816A7AQ35122575-AA56C9F1-8077-4F99-8AE8-2244BF1E399DQ35605511-26C12CE3-76C5-4792-8A15-8E0D3A67B4E5Q35666654-5E558F6C-7AF5-42FB-AD34-F1E22AFE378BQ35838927-43C6BF33-DDED-4582-A07F-C3EA08E2361FQ35909887-701EB332-DC4B-4CAA-8317-A76EFF9E4C41Q36118527-FF4DC38E-590A-480D-AA73-D17BBC321B59Q36281325-79ADC432-F4E5-4BB6-AA19-8928F8F2A3DAQ36282416-B95463D8-2E2C-4B13-BCE5-3E6F22AFFD4CQ36906590-281B885A-FCB4-47C3-A8FC-3204A1C27B9DQ36969157-60BCC4F1-5256-4784-86D1-EFC2D79E9C0DQ37125732-ED4D1DDB-EA30-4559-A6B6-2D334C5B41BCQ37220949-26AACA1D-B9CB-4B65-BAFE-76498EFDC1F4Q37681902-5736C30F-77FE-4C60-AB2D-8A9FB3F3EB21Q38211851-D189FE2A-8A2F-4CA7-9A51-096FDC2D38AEQ38618438-0FDB1A98-0A10-4A71-AF2D-2D6ECD07A75DQ38643410-8AE46AFE-7A04-4AF6-85C1-18A09EE4BDC7Q39124054-986C78F3-7439-4A12-B03E-215A9D8665C2Q39156593-19BA4943-9907-4971-9ED9-BFEEF8E91169Q39585356-F1CF4D0E-B242-4870-AA06-0B53469013BCQ40528471-D99D4D14-A370-4BB4-9EA0-E594DBA63FC8Q41043666-00A94E57-EFDE-49FC-9525-4598FEAC7DF0Q41558777-D77577CD-418B-4116-B6AE-2DFDC03C5AF4Q42694566-6DA55B24-5DAF-4F28-960B-F64DF20FEE36Q46099419-C4581C09-8A32-4EA9-8699-7464D611D713Q47098436-AB7C34E8-668D-408F-B0F6-C17D4DD014FEQ47232128-46B01A75-2432-4B63-8873-C0C0FDBFF29EQ47604044-96917756-A416-45AE-88E0-0FBE26BD2209Q48560747-8EF3B077-CC1C-44F4-993E-D2B1680B95A4Q52673716-D64A2DD6-5847-40DA-8828-39CD3A112762
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immunobiology of visceral leishmaniasis.
@ast
Immunobiology of visceral leishmaniasis.
@en
Immunobiology of visceral leishmaniasis.
@nl
type
label
Immunobiology of visceral leishmaniasis.
@ast
Immunobiology of visceral leishmaniasis.
@en
Immunobiology of visceral leishmaniasis.
@nl
prefLabel
Immunobiology of visceral leishmaniasis.
@ast
Immunobiology of visceral leishmaniasis.
@en
Immunobiology of visceral leishmaniasis.
@nl
P2860
P356
P1476
Immunobiology of visceral leishmaniasis.
@en
P2860
P356
10.3389/FIMMU.2012.00251
P577
2012-08-14T00:00:00Z